Enriqueta Felip-Font
Barcelona, CT, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 42 publications
Corrigendum to "Subcutaneous versus intravenous pembrolizumab, in combination with chemotherapy, for treatment of metastatic non-small-cell lung cancer: the phase III 3475A-D77 trial": [Ann Oncol 36 (2025) 775-785].
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: April 08, 2026
Efficacy and safety of subcutaneous and intravenous administration of atezolizumab in patients with non-small cell lung cancer, including early-stage, locally advanced or metastatic disease: Updated results of the IMscin001 and IMscin002 randomized studies.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: February 09, 2026
Assessing time to symptomatic progression, a patient-relevant efficacy endpoint, in the MARIPOSA study in non-small cell lung cancer.
Journal: European journal of cancer (Oxford, England : 1990)
Published: January 23, 2026
Somatic copy number alterations profiling in non-small cell lung cancer and their correlation with clinical efficacy in first-line treatment.
Journal: Genome medicine
Published: November 07, 2025
Managing lorlatinib together: An overview and practical guide for patients by ALK-positive NSCLC patients and medical experts.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: July 05, 2025
Subcutaneous versus intravenous pembrolizumab, in combination with chemotherapy, for treatment of metastatic non-small-cell lung cancer: the phase III 3475A-D77 trial.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: March 10, 2025
Reply to the Letter to the Editor regarding 'PFS, OS or toxicity: what is the most important factor in the treatment of EGFR-mutated lung cancer?' by T. Nishimura and H. Fujimoto.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: October 03, 2024
Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: April 05, 2024
Capmatinib plus nazartinib in patients with EGFR-mutated non-small cell lung cancer.
Journal: European journal of cancer (Oxford, England : 1990)
Published: March 18, 2024
Capmatinib plus nivolumab in pretreated patients with EGFR wild-type advanced non-small cell lung cancer.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: January 28, 2024
A pragmatic guide for management of adverse events associated with lorlatinib.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: December 19, 2023
SEOM 2022 clinical guidelines.
Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
Published: June 09, 2023
Last Updated: 09/26/2026